Alivus Life Sciences Limited has informed the Exchange about Business Responsibility & Sustainability Report for FY 2024-25
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alivus Life Sciences (formerly Glenmark Life Sciences, renamed on 17 December 2024) has filed its annual Business Responsibility & Sustainability Report for FY 2024-25, as required under SEBI's Listing Regulations. The company is a 100% API (Active Pharmaceutical Ingredients) manufacturer with standalone turnover of ₹23,869 million and net worth of ₹28,174 million, now a subsidiary of Nirma Limited. It operates 5 manufacturing plants domestically, exports 51.7% of revenue to over 75 countries, and serves 700+ clients including the world's top 20 generic pharma companies. The company has set long-term targets of Water Neutrality by 2027 and Carbon Neutrality by 2030, with 7% of capex and 9% of R&D spent on environmental improvements. One notable disclosure is a ₹15 lakh penalty from the Gujarat Pollution Control Board (closure direction at Ankleshwar plant, later revoked) and an improvement in permanent employee turnover to 20.77% from 25.48% in FY 2023-24.
This is a routine annual ESG compliance disclosure, not a material business event, so it is unlikely to move the stock on its own. However, the 51.7% export concentration, employee turnover improvement, sustainability targets, and the resolved GPCB regulatory issue offer useful context for investors evaluating operational resilience and long-term governance quality.